Renal / Liver Diseases

Proceedings of the Guideline Workshop 2019 –Strategies for the optimization of guideline

processes in diabetes, cardiovascular diseases and 

kidney diseases

 

Nikolaus Marx, Lars Ryde´n , Frank Brosius , Antonio Ceriello , Michael Cheung , Francesco Cosentino , Jennifer Green , Monika Kellerer , Susan Koob ,

Mikhail Kosiborod , Prashant Nedungadi , Helena W. Rodbard , Per Olav Vandvikm, Eberhard Standl , Oliver Schnell n

​

The Guideline Workshop 2019, held in October 2019 in Munich, Germany, had the purpose of facilitating discussion on strategies for optimization of guideline processes in diabetes amongst a group of representatives of renown national and international societies in the field of diabetes, cardiology, and nephrology.

Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication

 

Zachary Bloomgarden, Yehuda Handelsman

​

A somewhat underappreciated cause of optimism has been the evidence from the cardiovascular outcome trials

of type 2 diabetes (T2D) treatments that all the newer agents appear to improve aspects of renal function. 

The 2.6-year CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial randomizing 4401 persons with T2D, estimated

glomerular filtration rate (eGFR) 30-90 mL/min/1.73m2 (mean baseline 56), and angiotensin-converting-enzyme

inhibitor (ACEI) or angiotensin-receptor blocker (ARB)- treated macroalbuminuria (>300 mg/g creatinine) to canagliflozin

100 mg daily or placebo showed highly significant reduction in renal disease outcomes